Aytu BioPharma, Inc.
AYTU · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.8% | -39.3% | 11.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 69% | 75.3% | 62% | 52% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -7% | 2.2% | -3% | -28.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -20.4% | -24.3% | -15.9% | -112.5% |
| EPS Diluted | -2.16 | -2.86 | -5.11 | -74.01 |
| % Growth | 24.5% | 44% | 93.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |